Advair HFA in Healthy and HAPE Predisposed Subjects

Key facts

Sponsor

University of Colorado, Denver

Principal Investigator

James P Maloney, MD

Univ. of Colorado, Denver

Intervention

Advair HFA(drug)

Enrollment

60 target

Eligibility

18-50 years · All sexes

Timeline

2023 – 2026

Study locations (1)

• University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Collaborators

United States Department of Defense

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for High altitude pulmonary edema

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06894550
  Short-term Exposure to High Altitude in Patients With Asymptomatic Aortic Stenosis
  Insel Gruppe AG, University Hospital Bern
• ACTIVE NOT RECRUITINGNANCT06446427
  The Effect of Acute High Altitude Exposure on Rescuer Performance and Patient Care
  Insel Gruppe AG, University Hospital Bern
• RECRUITINGPHASE4NCT06498505
  HighCycle: Effect of Acetazolamide on Pulmonary Artery Pressure in Women Compared to Men
  University of Zurich
• ENROLLING BY INVITATIONNCT06557928
  Protocol for Evaluating Physiological and Psychological Adaptation Mechanisms in Tibetan Plateau Environments
  Peking Union Medical College Hospital
• ACTIVE NOT RECRUITINGNCT06129825
  Pharmacologic Induction of Tolerance for Hypoxia & Hypothermia
  University of Maryland, Baltimore
• RECRUITINGNCT06152744
  Evaluation of Membrane Lung Function in High-altitude Regions
  Beijing Chao Yang Hospital
• ENROLLING BY INVITATIONNANCT06133530
  Human Milk Oligosaccharides (HMOs) and Gut Microbiota, Immune System in Antarctica
  IU University of Applied Sciences
• RECRUITINGNANCT06852924
  Inhaled Nitric Oxide for High Amplitude Pulmonary Edema (HAPE)
  Novlead Inc.

See all trials for High altitude pulmonary edema →